Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseasesGiulio Cavalli, Charles A. Dinarello, Serena Colafrancesco et al.|Autoimmunity Reviews|2021Cited by 330
Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathiesPietro Maggi, Luca Massacesi, Martina Absinta et al.|Annals of Neurology|2018Cited by 245
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life SettingMariele Gatto, Roberto Gerli, Francesca Saccon et al.|Arthritis & Rheumatology|2020Cited by 113
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Andrea Doria, Laura Andréoli et al.|Journal of Autoimmunity|2017Cited by 102
A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational StudyAntonio Vitale, Luca Cantarini, Romina Gallizzi et al.|Frontiers in Pharmacology|2016Cited by 88